Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03710642 · ClinicalTrials.gov registry record · Phase 2
Prazosin for Agitation in Alzheimer's Disease
A Phase 2 study, sponsored by Alzheimer's Disease Cooperative Study (ADCS).
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT03710642: Completed Phase 2 study, sponsored by Alzheimer's Disease Cooperative Study (ADCS).
NCT03710642 is a Phase 2 study that has completed, run by Alzheimer's Disease Cooperative Study (ADCS). The registered enrollment target is 35 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03710642, a Phase 2 study, has completed, sponsored by Alzheimer's Disease Cooperative Study (ADCS).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
The study evaluates the effects of Prazosin on agitation in adults with Alzheimer's disease. Two thirds of the participants will participate in the medication portion, while one third will participate in the placebo portion
Primary Outcome
The ADCS-CGIC-A is the primary outcome measure. It will be anchored to disruptive agitation, the target behaviors in this study. It measures whether the effects of active treatment are substantial enough to be detected by a skilled and experienced clinician on the basis of a direct examination of the participant and an interview of the participant's primary caregiver and other LTC facility staff. The baseline assessment is qualitative therefore there is no score at baseline; post-baseline scores
Interventions
- DRUG Placebo oral capsule
- DRUG Prazosin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2018-10-23 |
| Est. Completion | 2022-01-05 |
| Phase | Phase 2 |
What the finished NCT03710642 record still lists
NCT03710642 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03710642 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03710642 about?
NCT03710642 is a clinical study titled "Prazosin for Agitation in Alzheimer's Disease". The study evaluates the effects of Prazosin on agitation in adults with Alzheimer's disease. Two thirds of the participants will participate in the medication portion, while one third will participate in the placebo portion
What is the current status of trial NCT03710642?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2018-10-23. Estimated completion is 2022-01-05.
What interventions are being tested in trial NCT03710642?
The interventions under investigation include: Placebo oral capsule (DRUG), Prazosin (DRUG).
Who is sponsoring clinical trial NCT03710642?
This trial is sponsored by Alzheimer's Disease Cooperative Study (ADCS), which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03710642's enrollment target sits among peer trials
35 1524th of 2000 higher than 462 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI